Ashley Allison: Trump is making up tariff strategy on the fly
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Wine producers in Italy's Valpolicella brace for US tariffs
By Oriana Boselli NEGRAR, Italy (Reuters) -Italy's wine producers, already struggling amid a slowing economy and a strengthening euro, face a further challenge after wine and spirits were left out of the U.S.-EU trade deal agreed on Sunday. Discussions are continuing regarding any tariff exemptions for the wines and spirits sectors in the framework trade deal, a senior European Commission official said on Monday, a day after the U.S. and EU agreed a 15% tariff on U.S. imports of most other goods from the European Union. Producers in the winemaking region of Valpolicella, in northern Italy, warn that on the top of any new tariff, their exports will be impacted by the depreciating dollar, which has lost more than 12% against the euro this year, making European goods more expensive for U.S. consumers. "This is already pretty bad," said Andrea Sartori of the Sartori winery in Negrar di Valpolicella, founded in 1898. "I'm very worried about the economy overall. And we all know that wine consumption doesn't thrive very well when we have seen economic crises in the past," Sartori told Reuters. "So this could be a domino effect that could hit the wine trade as well." The United States is the biggest export market for Italy's wine and spirits producers, generating sales of 2 billion euros ($2.3 billion) last year, or a quarter of their global sales, according to industry group Federvini. Lamberto Frescobaldi, president of Italian wine producer association UIV, said on Sunday that 15% tariffs on wine would result in a loss of 317 million euros ($372.63 million) over the next 12 months. Wine producers are already facing subdued domestic demand, with the Italian economy forecast to grow just 0.6% this year, according to national statistics bureau ISTAT, although premium wines are set to do better as deeper-pocketed consumers are less price sensitive. They include Valpolicella's top end Amarone wine. "Amarone is the least sensitive because it's already a premium wine with a pretty high price. So I don't think it would be a dramatic change," Sartori said. "I'm more worried about Valpolicella and Ripasso, which are mainstream, and a price increase could possibly damage the sales," he added (Additional reporting by Alex Fraser; Editing by Giselda Vagnoni and Susan Fenton)
Yahoo
20 minutes ago
- Yahoo
Why Nice Stock Popped Today
Key Points Nice acquired conversational and agentic artificial intelligence specialist Cognigy for $955 million. The two AI leaders combine to form a powerhouse in the customer experience niche. With Nice's AI-related and self-service sales already growing by 39% prior to the deal, the company is launching full-speed ahead into today's most important technology. 10 stocks we like better than Nice › Shares of enterprise software leader Nice (NASDAQ: NICE) rose 6% as of noon ET on Monday, according to data provided by S&P Global Market Intelligence. True to its artificial intelligence (AI) focus, Nice acquired agentic AI specialist Cognigy for $955 million this morning. This acquisition prompted a positive reaction from the market, and I think it is deserved. Nice: AI innovator, not disruptee Back in June, I wrote about Nice as a potential once-in-a-decade opportunity. At the end of the article, I explained, "It'll be of the utmost importance to keep an eye on Nice's AI sales in each quarterly update and ensure the company remains the AI innovator, not the disruptee." Acquiring Cognigy today, Nice reinforced its chances of remaining an AI innovator, rather than a disruptee. By adding Cognigy, Nice added new conversational and agentic capabilities to its customer experience platform, which accounts for 75% of its sales. The Cognigy AI platform offers its services in over 100 languages and serves more than 1,000 brands, including Adidas, Toyota Motor, and Nestle. Despite its start-up nature, Cognigy was already recognized as a leader in conversational AI according to rankings from Gartner Magic Quadrant and Forrester Wave reports. With Nice itself already counting 85 Fortune 100 companies as customers, this union creates an AI powerhouse in the realms of contact centers as a service and customer engagement in general. In the first quarter of this year, Nice grew its AI-related and self-service sales by 39%. Adding Cognigy's AI capabilities, client list, and cross-selling potential should only add fuel to this fire. Even after today's pop, Nice still trades at just 15 times free cash flow. This discounted valuation, paired with Cognigy's addition, keeps Nice a once-in-a-decade opportunity in my eyes. Should you invest $1,000 in Nice right now? Before you buy stock in Nice, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Nice wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 28, 2025 Josh Kohn-Lindquist has positions in Adidas Ag. The Motley Fool has positions in and recommends Nice. The Motley Fool recommends Gartner and Nestlé. The Motley Fool has a disclosure policy. Why Nice Stock Popped Today was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
20 minutes ago
- Yahoo
Unlocking Oncology's Future: 3 Trending Cancer Biotech Stocks with ‘Strong Buy' Ratings
Cancer remains one of the most relentless challenges in modern medicine. In 2025, over 2 million new cancer cases are expected to be diagnosed in the United States. More than 618,000 people will die from the disease, which is equivalent to about 1,700 deaths each day. The scale of this health crisis is driving substantial investments and innovation in cancer research and treatment. As a result, the global oncology market is projected to reach $208.9 billion in revenue by 2025, with forecasts suggesting it could surpass $900 billion by 2034. This growth is fueled by increased cancer incidence, advances in precision and immunotherapy drugs, and billions of dollars in new partnerships and funding, such as Bristol-Myers Squibb's (BMY) recent $11 billion stake in next-generation cancer therapies. More News from Barchart Warren Buffett Warns Inflation Turns Business Into 'The Upside-Down World of Alice in Wonderland' But Weeds Out 'Bad Businesses' Why GOOGL Stock May Be the Market's Next Big Winner Alphabet Posts Lower Free Cash Flow and FCF Margins - Is GOOGL Stock Overvalued? Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. High-potential cancer specialists like Elicio Therapeutics (ELTX), Cellectis (CLLS), and Autolus Therapeutics (AUTL) are earning coveted 'Strong Buy' analyst ratings. Despite this recognition, each remains well below large-cap valuations, which leaves ample room for sharp upside if upcoming clinical and regulatory catalysts play out in their favor. Could one of these under-the-radar biotech firms deliver the next big breakthrough in cancer treatment — and major upside for investors? Let's dive into these three cancer biotech stocks now. Elicio Therapeutics Elicio Therapeutics (ELTX) is a clinical-stage biotech pioneering immunotherapies for solid tumors, with a market capitalization of $158 million. ELTX has posted a YTD gain of 92.7%, and is up 102.6% over the past 52 weeks. Its price-book ratio stands at an elevated 17.6x, well above the sector median of 2.47x. Elicio's lead asset, ELI-002 7P, is advancing through the pivotal Phase 2 AMPLIFY-7P trial targeting pancreatic ductal adenocarcinoma (PDAC), with a critical interim analysis focused on disease-free survival slated for Q3 2025. This interim analysis is a key milestone for the company, particularly for its potential impact on PDAC. Ahead of this readout, H.C. Wainwright analyst Robert Burns reiterated a 'Buy' rating on shares and maintained his $13 price target. Elicio reported Q1 2025 R&D expenses of $7.8 million, a slight increase from $7.6 million in Q1 2024, tied primarily to the ongoing Phase 2 AMPLIFY-7P trial. General and administrative expenses grew to $3 million, up from $2.7 million due to higher personnel costs. The Q1 2025 net loss narrowed to $11.2 million, compared to $11.8 million in the same quarter last year, with a net loss per share improving to $0.87 from $1.15. Notably, ELTX augmented its financial position in Q2 by securing a $10 million senior secured note, extending its operational runway into early 2026 and granting the company flexibility for near-term initiatives. Analyst sentiment skews highly bullish as the two surveyed analysts assign ELTX a 'Strong Buy' rating, with an average price target of $12.50. This places the upside potential at approximately 26% from current levels. Cellectis Cellectis (CLLS) is a clinical-stage biotech company specializing in gene-edited cell therapies with a market capitalization of approximately $140 million. The stock has gained 60% in the year to date, and shares are up 25.2% in the past 52 weeks. Cellectis has a price-sales ratio of 2.26x, below the sector median of 3.6x, and a price-book ratio of 0.96x, significantly under the sector median of 2.47x, suggesting potential undervaluation relative to its peers. CLLS reported solid results for Q1 2025, with consolidated revenues and other income rising to $12 million from $6.5 million a year prior. This increase mainly stems from $5.9 million recognized under the AstraZeneca Joint Research Collaboration Agreement (AZ JRCA). Its cash reserves stood at $246 million as of March 31, 2025, projected to sustain operations well into the second half of 2027, providing ample runway for ongoing development. Research and development expenses slightly decreased to $21.9 million compared to the previous year, reflecting efficient management despite continued investment in pipeline advancement and manufacturing capabilities in Paris and Raleigh. Strategically, Cellectis' partnership with AstraZeneca is a cornerstone of its growth story. AstraZeneca's $140 million investment enhances Cellectis' financial footing and grants AstraZeneca exclusive rights to 25 genetic targets, with options to develop up to 10 candidate products. So far this collaboration is advancing two CAR-T programs aimed at hematological malignancies and solid tumors. Analyst sentiment is unanimously bullish, with the five surveyed analysts assigning Cellectis a consensus 'Strong Buy' rating. The average price target of $5.60 implies compelling upside of approximately 91% from the current share price. Autolus Therapeutics Autolus Therapeutics (AUTL) develops advanced autologous CAR-T cell therapies for blood cancers, with a market capitalization of $670 million. The stock is up 8.7% year-to-date, but down 45% over the past 52 weeks. Its price-sales ratio of 69.4xx is markedly above the sector's 3.54x median, while its 1.89x price-book ratio remains below group averages of 2.47x. In Q1 2025, Autolus reported $9 million in net product revenue, driven largely by the commercial rollout of AUCATZYL (Obe-cel), its lead CAR-T therapy, across 39 fully activated U.S. centers. Patient access continues to grow, capturing coverage for roughly 90% of U.S. medical lives as payer uptake accelerates. Costs of sales totaled $18 million, including delivered but as-yet-unrecognized product tied to deferred revenue and royalty obligations, a natural part of early stage commercial launches. Research and development expenses dropped to $26.7 million from $30.7 million year-over-year, with much of that shift driven by the transition of manufacturing expenses to sales costs. Loss from operations widened to $65.2 million due to launch investments, and net loss reached $70.2 million or $0.26 per share. On the regulatory front, Autolus scored a critical win in July as AUCATZYL secured European approval for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. This unlocks a larger addressable market and enhances the company's global competitive position in engineered cell therapies. The analyst outlook remains unequivocally positive as the nine surveyed analysts rate AUTL a consensus 'Strong Buy,' with a mean target of $9.84, implying 285% upside potential from current levels. Conclusion With major catalysts ahead and strong analyst backing, the odds favor upward momentum as data readouts and commercial expansion play out. Given their positioning and partnerships, these three stocks could deliver outsized gains in the coming quarters, especially if results come in strong. On the date of publication, Ebube Jones did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
